News

OCRF Researchers Discover Genomic Complexity and AKT Depend...

OCRF Researchers Discover Genomic Complexity and AKT Dependence in Serous Ovarian Cancer

January 20, 2012

01/20/2012                Dr. Doug Levine and Dr. Carol Aghajanian, both recipients of OCRF grants, were part of a project recently published in Cancer Discovery that studied AKT inhibition in ovarian cancer cell lines with various mechanisms of AKT pathway activation. Researchers found that some cell lines were responsive to AKT inhibitors, but depended greatly on other, co-existent, … Continued

Meet OCRF’s 2012 Grantees

Meet OCRF’s 2012 Grantees

January 3, 2012

OCRF has awarded $5.4 million in grants for ovarian cancer research this year. After receiving over 100 applications – the highest number in its history – OCRF and its prestigious Scientific Advisory Committee endeavored first and foremost to fund the best science. The Committee evaluated each proposal through intensive peer review, and selected a sound … Continued

Ovarian Cancer Research Fund Awards $5.4 Million in 2012 Re...

Ovarian Cancer Research Fund Awards $5.4 Million in 2012 Research Grants

January 3, 2012

OCRF receives record number of grant applications; continues to fund the best science New York, NY January 3, 2012— Ovarian Cancer Research Fund (OCRF) has awarded $5.4 million in grants for ovarian cancer research this year. After receiving over 100 applications – the highest number in its history – OCRF and its prestigious Scientific Advisory … Continued

New Genetic Mutation Increases Risk of Ovarian Cancer

New Genetic Mutation Increases Risk of Ovarian Cancer

August 17, 2011

08/17/2011Researchers in the United Kingdom have discovered a new genetic mutation that increases the risk for ovarian cancer.  This major finding was published online in the journal Nature Genetics on August 7th. Much like the BRCA1 and BRCA2 mutations, which were discovered in the 1990s and which also increase a woman’s risk for ovarian cancer, … Continued

Researchers Create Genetic "Map" of Ovarian Cancer

Researchers Create Genetic "Map" of Ovarian Cancer

July 1, 2011

In a paper published on June 30, 2011 in the journal Nature, researchers working as part of The Cancer Genome Atlas (TCGA) Research Network report that they have created a genetic “map” of ovarian cancer.  This important work, which is the largest study of any tumor type to date, will help researchers better understand the … Continued

2011 SGO News: GI Risk Clarified for Bevacizumab

2011 SGO News: GI Risk Clarified for Bevacizumab

May 1, 2011

Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.

2011 SGO News: Genetic Test May Spot Increased Risk for In...

2011 SGO News: Genetic Test May Spot Increased Risk for Inherited Ovarian Cancer

May 1, 2011

Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.

2011 SGO News: Menopause Symptoms Common after Gynecologic...

2011 SGO News: Menopause Symptoms Common after Gynecologic Cancer

May 1, 2011

Most survivors of gynecologic cancers have menopausal symptoms, and at least one in four takes replacement hormones, results of the first study of its kind showed.

2011 SGO News: Mutation Link to Ovarian Cancer Disputed

2011 SGO News: Mutation Link to Ovarian Cancer Disputed

May 1, 2011

Developers of a genetic-susceptibility test for ovarian cancer might have jumped the gun, according to an OCRF-funded research consortium that found no association between a KRAS mutation and risk of the cancer.

2011 SGO News: ESAs Linked to Mortality Risk in Ovarian Ca...

2011 SGO News: ESAs Linked to Mortality Risk in Ovarian Cancer

May 1, 2011

Cancer recurrence and death occurred significantly more often in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs), data from a retrospective cohort review showed.

2011 SGO News: PARP Inhibitor Active in Ovarian Cancer

2011 SGO News: PARP Inhibitor Active in Ovarian Cancer

May 1, 2011

Almost half of patients with heavily pretreated ovarian cancer benefited from an investigational PARP inhibitor, results of a phase I study showed.

2011 SGO News: MicroRNA May Help Predict Ovarian Cancer Re...

2011 SGO News: MicroRNA May Help Predict Ovarian Cancer Response

May 1, 2011

Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of a small study reported here.